HIV Prevention

Resource Center

Clinical Insights

treatment

Brooke Nichols, PhD, on Measuring PrEP Program Effectiveness Using Routine Data

03/17/2022

In this podcast, Brooke Nichols, PhD, answers our questions about her team's novel and pragmatic metric to evaluate and compare pre-exposure prophylaxis program effectiveness using routine...

03/17/2022

Pre-Exposure Prophylaxis

Kathleen Ryan, PhD, on Rapid PrEP Scale-Up and its Impact on HIV Testing Rates

01/20/2022

Kathleen Ryan, MD

Kathleen Ryan, PhD, answered our questions about her study, which indicated that rapid scale-up of PrEP was possible without the consequence of reduced HIV testing among Australian gay, bisexual, and other...

01/20/2022

prevention

Jason Ong, PhD, MBBS, on the Burden of STIs Among PrEP Users

01/13/2022

Jason Ong, PhD, MBBS

Jason J. Ong, PhD, MBBS, from the London School of Hygiene and Tropical Medicine, answers our questions about his team’s research on STI prevalence and incidence among new and persistent users of...

01/13/2022

HIV Prevention

Daniel R. Kuritzkes, MD, on HIV Resistance After PrEP

10/14/2021

He talks about HIV resistance in the context of pre-exposure prophylaxis use, how common it is, and how PrEP might influence subsequent therapies.

10/14/2021

HIV Prevention

Hyman Scott, MD on an Overview of PrEP Therapy

07/20/2018

Dr Hyman Scott from the UCSF-Glastone Center for AIDS Research discusses pre-exposure prophylaxis (PrEP) therapy, its indications, and clinical data surrounding its use.

07/20/2018

HIV

PrEP With Dr Martin Holt: Unexpected Findings From His Study

06/18/2018

A new study of more than 27,000 MSM has indicated that increased HIV PrEP use has unexpectedly led to decreased condom use among men not using PrEP. Consultant360 spoke with lead study author Martin Holt,...

06/18/2018

For more infectious diseases content, visit the Resource Center

Pre-exposure prophylaxis (PrEP) is a preventive medication administered intravenously or orally to reduce the risk of human immunodeficiency virus (HIV) infection that may occur following sex or injection drug use.

For more infectious diseases content, visit the Resource Center

Any licensed health care provider can prescribe PrEP. Among clinicians who are most likely to prescribe PrEP are:

primary care providers; internal medicine specialists; infectious disease specialists

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- had a partner with HIV

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- had sex without consistently using a condom

For more infectious diseases content, visit the Resource Center

Individuals at risk of HIV transmission include:

People who have had anal or vaginal sex in the past 6 months and:
- have been diagnosed with a sexually transmitted disease in the past 6 months

For more infectious diseases content, visit the Resource Center

Individuals who are at risk of HIV transmission include:

Individuals who inject drugs, have an injection partner with HIV, or share needles, syringes, or other drug injection equipment

For more infectious diseases content, visit the Resource Center

Individuals who are at risk of HIV transmission include:

Individuals who have previously been prescribed PrEP, have reported continued risky behavior, or previously used multiple courses of PrEP

For more infectious diseases content, visit the Resource Center

The HIV Risk Incidence Index for Men Who Have Sex With Men (HIRI-MSM) and Injection Drug Users Risk Index (IDU) are often used to stratify risk in patients.

For more infectious diseases content, visit the Resource Center

PrEP may reduce HIV transmission from sex by 99% when taken as prescribed.

For more infectious diseases content, visit the Resource Center

The use of PrEP among recommended users increased from 3% in 2015 to 25% in 2020.

For more infectious diseases content, visit the Resource Center

Sources:

For more infectious diseases content, visit the Resource Center

HIV Prevention Snapshot

Reviewed by Daniel Erias, MD and Jeffrey Kwong, DNP, MPH, AGPCNP-BC

Research Summaries

Research Summary

Research Summary

Dapivirine Ring, Oral PrEP Show Safety in Second-Trimester Pregnancy

04/06/2026

Kate Young

In a phase 3b trial, monthly dapivirine ring and daily oral PrEP were assessed for safety, adherence, and acceptability in pregnancy.

04/06/2026

Research Summary

Research Summary

Comparing CBO, DTC Delivery of the Keep It Up! Digital HIV Prevention Program

02/09/2026

Anthony Calabro, MA

A type III hybrid effectiveness–implementation trial compared community-based organization versus direct-to-consumer delivery of the Keep It Up! digital HIV prevention intervention for young men who have...

02/09/2026

Research Summary

Research Summary

Study: Prescribing PrEP Via Telemedicine a Major Component of HIV Prevention in the United States

01/19/2026

Ashton L. Stahl

A large US cohort study evaluated the scale, patient characteristics, and retention outcomes of telemedicine-delivered HIV preexposure prophylaxis (PrEP), offering clinicians new data on how telePrEP is...

01/19/2026

Disease State Pillar

Disease State Pillar

HIV Management: A Practical Guide for Primary Care

12/09/2025

Miranda Manier, BA

Start fast, suppress durably, and think beyond the viral load: this primary care–focused guide covers diagnosis, same-day antiretroviral therapy, monitoring, opportunistic infection prevention, vaccines,...

12/09/2025

Research Summary

Emergency Department PrEP Initiation Does Not Improve Uptake or Retention in Pilot Trial

10/09/2025

Miranda Manier, BA

A pilot randomized trial found that offering immediate pre-exposure prophylaxis (PrEP) initiation with a 28-day starter pack in the emergency department did not improve PrEP use or retention compared with...

10/09/2025

May 2026

Current Issue

May 2026